Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Royalty Pharma Plc Cl A (RPRX)

Royalty Pharma Plc Cl A (RPRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 15,251,896
  • Shares Outstanding, K 593,459
  • Annual Sales, $ 2,355 M
  • Annual Income, $ 1,135 M
  • EBIT $ 1,544 M
  • EBITDA $ 1,564 M
  • 60-Month Beta 0.47
  • Price/Sales 6.45
  • Price/Cash Flow 5.60
  • Price/Book 1.48

Options Overview Details

View History
  • Implied Volatility 37.50% ( +2.35%)
  • Historical Volatility 15.92%
  • IV Percentile 79%
  • IV Rank 55.04%
  • IV High 58.59% on 06/13/24
  • IV Low 11.67% on 08/19/24
  • Put/Call Vol Ratio 0.02
  • Today's Volume 91
  • Volume Avg (30-Day) 258
  • Put/Call OI Ratio 0.11
  • Today's Open Interest 11,301
  • Open Int (30-Day) 13,694

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 1.11
  • Number of Estimates 2
  • High Estimate 1.12
  • Low Estimate 1.09
  • Prior Year 1.15
  • Growth Rate Est. (year over year) -3.48%

Price Performance

See More
Period Period Low Period High Performance
1-Month
25.10 +2.16%
on 11/15/24
28.36 -9.58%
on 11/06/24
-2.34 (-8.35%)
since 10/18/24
3-Month
25.10 +2.16%
on 11/15/24
29.37 -12.69%
on 08/30/24
-1.53 (-5.62%)
since 08/16/24
52-Week
25.10 +2.16%
on 11/15/24
31.66 -18.99%
on 02/27/24
-0.96 (-3.60%)
since 11/17/23

Most Recent Stories

More News
Royalty Pharma Announces Inaugural Prize for Impact in Healthcare

RPRX : 25.72 (+0.08%)
3 High-Yield Dividend Stocks You Can Buy With $130 Now and Hold at Least a Decade

This has been an amazing year for stocks. From the end of 2023 through Nov. 12, the benchmark S&P 500 index climbed 25% higher.

RPRX : 25.72 (+0.08%)
BIPC : 44.03 (+2.04%)
BIP : 34.57 (+1.08%)
O : 56.67 (+0.23%)
Royalty Pharma to Acquire Royalty Interest in Geron’s RYTELO for $125 Million

RPRX : 25.72 (+0.08%)
Royalty Pharma Reports Third Quarter 2024 Results

RPRX : 25.72 (+0.08%)
Royalty Pharma and Syndax Pharmaceuticals Enter Into $350 Million Royalty Funding Agreement for Niktimvo

RPRX : 25.72 (+0.08%)
3 Dividend Growth Stocks to Buy Now for a Lifetime of Passive Income

Buy these stocks now, and the yield on your original investment could reach a double-digit percentage long before you retire.

RPRX : 25.72 (+0.08%)
HTGC : 18.90 (-0.11%)
ADM : 53.24 (-0.21%)
Royalty Pharma to Announce Third Quarter 2024 Financial Results on November 6, 2024

RPRX : 25.72 (+0.08%)
Royalty Pharma Declares Fourth Quarter 2024 Dividend

RPRX : 25.72 (+0.08%)
2 No-Brainer Dividend Stocks to Buy With $100 in October

With their high yields and strong underlying businesses, these stocks are hard to pass up.

RPRX : 25.72 (+0.08%)
T : 23.02 (+1.50%)
2 High-Yield Dividend Stocks Near 52-Week Lows: Are They Buys Now?

These dividend-paying stocks offer hard-to-find high yields, but that doesn't necessarily make them good stocks to buy now.

RPRX : 25.72 (+0.08%)
WU : 10.99 (+1.38%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Royalty Pharma plc is a funder of biopharmaceutical industry. The compnay's portfolio includes royalties on commercial products, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta and Vertex's Kalydeco, Symdeko...

See More

Key Turning Points

3rd Resistance Point 26.80
2nd Resistance Point 26.34
1st Resistance Point 26.02
Last Price 25.72
1st Support Level 25.24
2nd Support Level 24.78
3rd Support Level 24.46

See More

52-Week High 31.66
Fibonacci 61.8% 29.15
Fibonacci 50% 28.38
Fibonacci 38.2% 27.60
Last Price 25.72
52-Week Low 25.10

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar